ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT03360006
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center /ID# 160701, Houston, Texas, United States
🇺🇸Northwestern /ID# 171098, Chicago, Illinois, United States
🇺🇸University of California, Davis Comprehensive Cancer Center /ID# 202729, Sacramento, California, United States
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 747
- Registration Number
- NCT03345823
- Locations
- 🇺🇸
Baylor Scott & White Center for Inflammatory Bowel Diseases /ID# 170161, Dallas, Texas, United States
🇺🇸Duplicate_Rush University Medical Center /ID# 165470, Chicago, Illinois, United States
🇺🇸University of Washington /ID# 164646, Seattle, Washington, United States
A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain
- Conditions
- Endometriosis
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 11
- Registration Number
- NCT03343067
- Locations
- 🇺🇸
Quad Clinical Research, LLC /ID# 168294, Chicago, Illinois, United States
🇺🇸Seattle Reproductive Medicine /ID# 171079, Seattle, Washington, United States
🇺🇸Central Ohio Clinical Research /ID# 170750, Columbus, Ohio, United States
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
- Conditions
- Crohn's Disease
- Interventions
- Drug: Matching Placebo for Upadacitinib
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 624
- Registration Number
- NCT03345836
- Locations
- 🇦🇷
Cardio Alem /ID# 211284, San Isidro, Buenos Aires, Argentina
🇺🇸Facey Medical Foundation /ID# 203137, Mission Hills, California, United States
🇺🇸CB Flock Research Corporation /ID# 166220, Mobile, Alabama, United States
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 526
- Registration Number
- NCT03345849
- Locations
- 🇦🇺
Fiona Stanley Hospital /ID# 171513, Murdoch, Western Australia, Australia
🇺🇸Velocity Clinical Research - Salt Lake City /ID# 166076, West Jordan, Utah, United States
🇺🇸Rush University Medical Center /ID# 165497, Chicago, Illinois, United States
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 350
- Registration Number
- NCT03342144
- Locations
- 🇦🇹
Hanusch Krankenhaus /ID# 221151, Wien, Austria
🇩🇪Praxis Dr. Kreher /ID# 202604, Bad Liebenwerda, Brandenburg, Germany
🇩🇪Friedrich-Ebert-Krankenhaus GmbH /ID# 206206, Neumuenster, Schleswig-Holstein, Germany
Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
- Conditions
- Hepatitis C Virus (HCV)
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1095
- Registration Number
- NCT03341871
- Locations
- 🇯🇵
Abbvie Japan /ID# 161985, Tokyo, Japan
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
- Conditions
- Non-infectious Intermediate, Posterior and Panuveitis
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 158
- Registration Number
- NCT03339102
- Locations
- 🇰🇷
Yeungnam University Med Ctr /ID# 201361, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷Pusan National University Hosp /ID# 202026, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷Soon Chun Hyang University Cheonan Hospital /ID# 204551, Cheonan, Chungcheongnamdo, Korea, Republic of
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 95
- Registration Number
- NCT03339128
- Locations
- 🇪🇸
Hospital Universitario Dr. Peset /ID# 236755, Valencia, Spain
🇺🇸Duplicate_VVCRD Research /ID# 234606, Garden Grove, California, United States
🇺🇸Frederick County Pediatrics /ID# 234519, New Market, Maryland, United States
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
- Conditions
- PsoriasisAnkylosing Spondylitis (AS)Rheumatoid Arthritis (RA)
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 224
- Registration Number
- NCT03339089
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital /ID# 210820, Hangzhou, Zhejiang, China
🇨🇳The Second Hospital of Jiaxing /ID# 210744, Jiaxing, Zhejiang, China
🇨🇳Sichuan Provincial orthopedic hospital /ID# 209341, Chengdu, China